Atherosclerosis, degenerative aortic stenosis and statins

Area of Science:

• Cardiology
• Valvular Heart Disease
• Pharmacology

Background:

• Aortic stenosis is the most prevalent valvular heart disease in Western adults, typically treated with aortic valve replacement.
• The pathophysiology of degenerative aortic stenosis (DAS) involves inflammation and lipid infiltration, similar to atherosclerosis, suggesting potential benefits of statins.
• Previous retrospective studies indicated statin efficacy, but prospective trials yielded conflicting results.

Purpose of the Study:

• To evaluate the efficacy of statins in slowing the progression of degenerative aortic stenosis (DAS).
• To clarify the role of statins in managing aortic stenosis based on current clinical trial evidence.

Main Methods:

• Review of retrospective studies and large-scale, randomized controlled trials (RCTs) such as SEAS and ASTRONOMER.
• Analysis of pathophysiological links between aortic stenosis, atherosclerosis, and lipid metabolism.

Main Results:

• Large RCTs, including SEAS and ASTRONOMER, found no significant effect of statins on the progression of aortic stenosis.
• Despite shared risk factors and histopathological patterns with atherosclerosis, DAS and coronary artery disease may evolve differently.

Conclusions:

• Statins are not recommended for patients with valvular aortic stenosis unless they have conventional indications for lipid-lowering treatment.
• The common pathogenetic background of coronary artery disease and DAS does not translate to similar treatment responses with statins.